An anonymous director reports

RAKOVINA THERAPEUTICS ANNOUNCES $1.5 MILLION PRIVATE PLACEMENT

Rakovina Therapeutics Inc. has arranged a non-brokered private placement offering of up to $1.5-million.

Pursuant to the offering, Rakovina will issue up to 15 million equity units at an offering price of 10 cents per unit, with each unit consisting of one common share and one-half of one common share purchase warrant. Each whole warrant will entitle the holder to acquire one additional common share at an exercise price of 20 cents, exercisable for a period of 24 months from issuance.

Proceeds from the offering will be used to advance Rakovina's pipeline, with a primary focus on in vivo ADME and efficacy testing for the kt-5000AI dual ATR/mTOR inhibitor program, and continued AI-driven (artificial intelligence) lead optimization through the company's collaboration with Variational AI. Funds will also support advancement of the kt-3000 LNP formulation program through in vitro and in vivo characterization, continuing kt-2000AI compound development, and the continued expansion of the company's AI-enabled drug discovery collaborations. Remaining proceeds will be used for general working capital purposes.

The units will be sold on a non-brokered private placement basis in accordance with applicable Canadian securities laws and under applicable exemptions from prospectus and registration requirements, and the securities will be subject to resale restrictions for a period of four months plus one day from the date of issue.

About Rakovina Therapeutics Inc.

Rakovina is a biopharmaceutical research company focused on the development of innovative cancer treatments. The company's work is based on unique technologies for targeting the DNA-damage response powered by AI using validated, proprietary platforms. By using AI, Rakovina can review and optimize drug candidates at a much greater pace than ever before.

The company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.

We seek Safe Harbor.